GJB2 and neoplasm: In the TCGA cohort, univariate analysis showed that tumor size (HR, 3.643; 95% CI, 1.992–6.904; p < 0.001), lymph node involvement (HR, 2.695; 95% CI, 1.358–5.349; p = 0.005), FIGO stage (HR, 1.861; 95% CI, 1.166–2.970; p = 0.009), lymphovascular invasion (HR, 10.041; 95% CI, 2.361–42.700; p = 0.002), distant metastasis (HR, 3.141; 95% CI, 1.866–5.289; p < 0.001), and high GJB2 expression (HR, 1.694; 95% CI, 1.053–2.728; p = 0.030) were correlated with patient prognosis.